Phase-2 Proof Spurs a Play on Avalo’s IL-1β Opportunity — Buy on Dips, Aim for Clinical Re-Rating
Avalo Therapeutics' positive Phase 2 readout for abdakibart in hidradenitis suppurativa and a $375M financing have materially de-risked the story and created a clear development path toward Phase 3 and follow-on pipeline candidates. At a market cap near $1.02B and a current price of $19.16, the stock looks primed for a clinical re-rating while stil…